Medsider: Learn from MedTech and HealthTech Experts

Planning Your Regulatory Pathway Around Your Product Roadmap: Interview with Virtual Incision CEO John Murphy

April 11, 2022 Scott Nelson
Medsider: Learn from MedTech and HealthTech Experts
Planning Your Regulatory Pathway Around Your Product Roadmap: Interview with Virtual Incision CEO John Murphy
Show Notes

In this episode of Medsider Radio, we sat down with John Murphy, President and CEO of Virtual Incision.

With a background in life sciences, aerospace, private equity, and venture capital, John co-founded Virtual Incision in 2006. The company makes miniature, portable robots that can be used to perform specific operations. The first iteration is designed for colon resections, with new variations planned for the future.

In this discussion,  John shares tips on how to raise funds as an early-stage medical device company, planning a regulatory pathway that complements your product roadmap, and how to follow a dual-track approach to exiting (warning: it’s a lot of work).

Before we jump into the conversation, I wanted to mention a few things:

If you’re into learning from proven medtech and healthtech leaders, and want to know when new content and interviews go live, head over to Medsider.com and sign up for our free newsletter. You’ll get access to gated articles, and lots of other interesting healthcare content.

Second, if you want even more inside info from proven experts, think about a Medsider premium membership. We talk to experienced healthcare leaders about the nuts and bolts of running a business and bringing products to market. This is your place for valuable knowledge on specific topics like seed funding, prototyping, insurance reimbursement, and positioning a medtech startup for an exit.

In addition to the entire back catalog of Medsider interviews over the past decade, Premium members get exclusive Ask Me Anything interviews and masterclasses with some of the world’s most successful medtech founders and executives. If you’re interested, go to medsider.com/subscribe to learn more.

Lastly, here's the link to the full interview with John if you'd rather read it instead.